BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21966591)

  • 1. Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care.
    Tang B; Patel MM; Wong RH; Wood D; Wong CO; Wu D; Khong PL; Wong CY
    Int J Mol Imaging; 2011; 2011():942063. PubMed ID: 21966591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of FDG PET/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics.
    Han EJ; O JH; Yoon H; Ha S; Yoo IR; Min JW; Choi JI; Choi BO; Park G; Lee HH; Jeon YW; Min GJ; Cho SG
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Acta Radiol; 2015 Oct; 56(10):1230-5. PubMed ID: 25387723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of three evaluation methods of ¹⁸F-FDG PET/CT in detecting bone marrow infiltration in patients with newly diagnosed diffuse large B-cell lymphoma].
    Bai J; Zhang Y; Duan M; Li J; Cao X; Cai H; Zhuang J; Chen M; Zhou D; Zhu Z; Zhang W
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):489-92. PubMed ID: 26134014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma.
    Kim HY; Kim JS; Choi DR; Kim HS; Kwon JH; Jang GD; Kim JH; Jung JY; Song HH; Lee YK; Min SK; Hwang HS; Kim HJ; Zang DY; Kim HJ
    Cancer Res Treat; 2015 Jul; 47(3):458-64. PubMed ID: 25648095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using
    Hao B; Zhao L; Luo NN; Ruan D; Pang YZ; Guo W; Fu H; Guo XY; Luo ZM; Wu J; Chen HJ; Wu H; Sun L
    BMC Cancer; 2018 Nov; 18(1):1192. PubMed ID: 30497426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Simonitsch-Klupp I; Raderer M; Mayerhoefer ME
    Acad Radiol; 2018 Apr; 25(4):453-460. PubMed ID: 29199055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma.
    Perry C; Lerman H; Joffe E; Sarid N; Amit O; Avivi I; Kesler M; Ben-Ezra J; Even-Sapir E; Herishanu Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2910. PubMed ID: 26945387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma.
    Newman EN; Jones RL; Hawkins DS
    Pediatr Blood Cancer; 2013 Jul; 60(7):1113-7. PubMed ID: 23192939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
    Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
    Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?
    Salaun PY; Gastinne T; Bodet-Milin C; Campion L; Cambefort P; Moreau A; Le Gouill S; Berthou C; Moreau P; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1813-21. PubMed ID: 19499219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD
    Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.
    Ross RW; Halabi S; Ou SS; Rajeshkumar BR; Woda BA; Vogelzang NJ; Small EJ; Taplin ME; Kantoff PW;
    Clin Cancer Res; 2005 Nov; 11(22):8109-13. PubMed ID: 16299243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter.
    Kand PG; Tiwari BP; Basu S; Asopa RV; Nayak UN
    Indian J Cancer; 2010; 47(4):380-4. PubMed ID: 21131749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.